Ticker

Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand.

Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain

Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply

Calgary, Alberta – TheNewswire - April 14, 2026 – Aurwest Resources Corporation (“ Aurwest ” or the “ Company ”) ( CSE: AWR ) is pleased to announce that the Company has entered into a Definitive Option and Joint Venture Agreement (the “ Agreement ”) with Pacific Bay Minerals Ltd. (TSXV: PBM) whereby Aurwest has acquired an option to earn, subject to the satisfaction of conditions, an undivided interest of up to 50%…